secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001453687-25-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics FY2024 net loss $77.4M; cash $214.3M; Phase 3 MG trial on track
--------------------------------------------------------------------------------

- Net loss of $77.4M ($4.48 loss per share) vs $219.7M loss in FY2023; R&D expenses $45.1M.
- Cash, equivalents and restricted cash $214.3M at Dec 31, 2024; expected to fund operations into mid-2027.
- Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; FDA SPA agreement secured.
- Preliminary Phase 2 SLE data expected 2H25; Phase 2 pediatric basket trial to initiate 2H25 in select autoimmune indications.
- Dosing ongoing in first-in-human Phase 1 trial of Descartes-15 for multiple myeloma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000059/0001453687-25-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000059/rnac-20250313.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer